Comparative Pharmacology
Head-to-head clinical analysis: LAZCLUZE versus TURQOZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAZCLUZE versus TURQOZ.
LAZCLUZE vs TURQOZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LAZCLUZE (lazertinib) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that irreversibly binds to and inhibits EGFR tyrosine kinase, including mutant forms with T790M resistance mutations and exon 19 deletions, thereby blocking downstream signaling pathways involved in tumor cell proliferation and survival.
TURQOZ is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.
20 mg orally once daily with or without food.
400 mg orally once daily.
None Documented
None Documented
The terminal elimination half-life of Lazcluze is approximately 24-30 hours, supporting once-daily dosing with steady-state achieved within 5-7 days.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment
Lazcluze is primarily eliminated via biliary excretion into feces, with approximately 70-80% of the administered dose recovered as unchanged drug in feces. Renal elimination accounts for less than 10% of the dose, with less than 1% excreted unchanged in urine.
Primarily renal (80% unchanged) with 10% fecal, 5% biliary, 5% other
Category C
Category C
Unknown
Unknown